Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007010498) COMPOSITIONS FOR REDUCING THE INCIDENCE OF DRUG INDUCED ARRHYTHMIA
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/010498 International Application No.: PCT/IB2006/052496
Publication Date: 25.01.2007 International Filing Date: 20.07.2006
IPC:
A61K 31/496 (2006.01) ,A61K 31/616 (2006.01) ,A61K 45/06 (2006.01) ,A61P 9/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
60
Salicylic acid; Derivatives thereof
612
having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
616
by carboxylic acids, e.g. acetylsalicylic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
06
Antiarrhythmics
Applicants:
THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza Cincinnati, OH 45202, US (AllExceptUS)
SPRAFKA, Joseph, Michael, II [US/US]; US (UsOnly)
GOULART-BRUM, Jose, Mauro [BR/US]; US (UsOnly)
Inventors:
SPRAFKA, Joseph, Michael, II; US
GOULART-BRUM, Jose, Mauro; US
Common
Representative:
THE PROCTER & GAMBLE COMPANY; c/o Eileen L. Hughett The Procter & Gamble Company Winton Hill Business Center 6110 Center Hill Road Cincinnati, OH 45224, US
Priority Data:
60/701,55522.07.2005US
Title (EN) COMPOSITIONS FOR REDUCING THE INCIDENCE OF DRUG INDUCED ARRHYTHMIA
(FR) COMPOSITIONS PERMETTANT DE REDUIRE L'INCIDENCE D'UNE ARYTHMIE D'ORIGINE MEDICAMENTEUSE
Abstract:
(EN) In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class HI antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and/or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg.
(FR) La présente invention concerne de nouveaux procédés et de nouvelles préparations permettant de traiter et de prévenir l'incidence d'une proarythmie d'origine médicamenteuse, y compris des torsades de pointes. Les procédés et les préparations comprennent une combinaison d'un médicament qui induit des torsades de pointes, tel que des anti-arythmisants de classe HI, certains agents antimicrobiens, des antihistaminiques, des antidépresseurs, des antipsychotiques, des diurétiques, avec de l'aspirine et/ou une statine. Dans certains modes de réalisation, les compositions et les procédés de traitement comprennent de l'azimilide et de l'aspirine et/ou une statine. Ces compositions peuvent être administrées par différentes voies, notamment par voie orale. Dans certains modes de réalisation dans lesquels l'anti-arythmisant est de l'azimilide, celui-ci peut être administré par voie orale à une dose allant d'environ 25 mg à environ 300 mg.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
NO20080890NZ564463MXMX/a/2008/001063KR1020080017489IL188831AR055091
MA29622PE2007-0369EP1906966BRPI0613670-2JP2009502773RU02376994
CN101227908CA2615975AU2006271230ID048.0581MYPI 20063463TH89523
IN425/DELNP/2008